Tryptamine Therapeutics Ltd (ASX:TYP, OTC:TYPTF) has safely administered its TRP-8803 IV-infused psilocin therapy to three participants from an obese population for over 140 minutes each, completing its Phase 1b study into an obese population.
The open label study undertaken at CMAX Clinical Research in Adelaide was designed to examine whether there are any difference in pharmacokinetic parameters compared to previous studied non-obese subjects.
TYP expects the results to be ready before the end of the year, supporting TRP-8802’s application in obese populations while also providing valuable and cost-effective dose optimisation data for a Phase 2 clinical program.
The planning for said program is well advanced – TYP expects to provide updates on its nature and timing in the coming months.
Considerable research potential
“To have completed subject dosing over such a short timeframe is a great achievement and also highlights the considerable potential for future research opportunities using TRP-8803,” Tryptamine Therapeutics CEO Jason Carroll said.
“All subjects that underwent treatment did so safely and were all discharged after the administration, marking the achievement of an important early-stage clinical objective and also confirming the potential of TRP-8803 to deliver improved health outcomes in a timely manner.
“We look forward to receiving the final dataset from CMAX, which will assist in our ongoing planning for Phase 2 trials to explore the efficacy of the application over specific unmet need states with large addressable market opportunities.”
“The completion of subject dosing for the Phase 1b study will now allow the company to expand its proprietary dataset across a broad patient population in a timely and cost-effective manner, as we continue to diligently execute on our comprehensive clinical development pathway for TRP-8803.”
Tryptamine is assessing its lead asset TRP8803 as a potential neuroplasticity aid that could provide therapeutic benefits for those suffering from pain and mental health-related conditions, including binge eating, irritable bowel syndrome and fibromyalgia.
Read: Tryptamine Therapeutics achieves full patient response in TRP-8802 Phase 2a fibromyalgia trial